Clinical Research
News & Careers
Search the Site
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login           Employers:  Register | Login   

By Industry | By Industry Segment | By Services and Suppliers | By Location | Profile Search
 Company Profile


Galderma Laboratories 

14501 N. Freeway

Fort Worth  Texas  76177  U.S.A.
Phone: 817-961-5000 Fax:



 Company News
Galderma Laboratories Announces Positive Phase 3 Trial Results Of Investigational Adapalene 0.3%/Benzoyl Peroxide 2.5% (0.3% A/BPO) For The Treatment Of Acne 3/20/2015 10:28:59 AM
Galderma Laboratories Announces Availability Of Soolantra® (ivermectin) Cream, 1% 2/17/2015 2:15:17 PM
Galderma Laboratories Launches Its First Over-The-Counter Acne Regimen, Benzac® Acne Solutions 1/5/2015 10:25:09 AM
Galderma Laboratories Receives FDA Approval Of Novel Treatment Option For Rosacea Patients 12/23/2014 9:09:47 AM
Galderma Laboratories Release: The Cetaphil® Brand Revamps RestoraDerm® Product Line 11/17/2014 11:15:25 AM
Ipsen (IPN.PA) And Galderma Laboratories Become Exclusive Partners For Development And Marketing Of Neurotoxins In The US, Canada, Brazil And Europe 7/11/2014 9:08:57 AM
Galderma Laboratories Unites With Hit Music Artists And PACER’S National Bullying Prevention Center To Raise The Volume Around Bullying Prevention 7/8/2014 6:58:45 AM
Galderma Laboratories To Gain Rights To Restylane, Perlane, Sculptra And Dysport In The United States And Canada 5/28/2014 11:55:13 AM
Galderma Laboratories Announces Positive Results Of Phase 3 Trials Of Investigational Ivermectin 1% Targeting Papulopustular Rosacea 3/24/2014 7:30:20 AM
Bioventus Acquires DUROLANE® Assets From Galderma 2/4/2014 9:35:19 AM